What We're Reading: Page 92
Industry reads hand-picked by our editors
Jan 09, 2023
-
Bloomberg
Billionaires for a ‘Hot Minute’: Biotech Slump Whipsaws Boston Founders
-
Stat News
Day One drug shrinks tumors in common pediatric brain cancer
-
The Wall Street Journal
71-Year-Old Cancer Patient Broke Trial Age Limits for a Chance at a Cure
-
Evaluate Vantage
Valrox shows signs of plateauing
Jan 06, 2023
-
The Financial Times
A pharma partnership that brought a breakthrough in breast cancer
-
Evaluate Vantage
The biggest-selling drugs of 2023
-
The Wall Street Journal
New Biden Law Won’t Kill Drug Cures. It Will Reshape Them.
-
Bloomberg
The US Keeps Offering China Its Covid Vaccines. China Keeps Saying No
Jan 05, 2023
Jan 04, 2023
-
Evaluate Vantage
After 33 years Geron could have an approved drug
-
The Wall Street Journal
Healthcare Deal-Making Set to Surge in 2023
-
Science
Revised clinical trial form for Alzheimer’s antibody warned of fatal brain bleeds
-
Associated Press
FDA finalizes rule expanding availability of abortion pills
Jan 03, 2023
-
The Wall Street Journal
Drug Prices Reach New High — in the Millions
-
Financial Times
GSK on hunt for attractive biotechs ‘hiding in plain sight’
-
The New York Times
An Architect of Biden’s Antitrust Push Is Leaving the White House
-
Wired
A Drug to Treat Aging May Not Be a Pipe Dream
Dec 22, 2022
-
Science
Scientists tie third clinical trial death to experimental Alzheimer’s drug
-
The Wall Street Journal
Many Hospitals Get Big Drug Discounts. That Doesn’t Mean Markdowns for Patients.
-
Evaluate Vantage
Biotech tries everything it can in Nash
-
Nature
After AlphaFold: protein-folding contest seeks next big breakthrough
Dec 21, 2022
-
The Wall Street Journal
Two Biotech CEOs Indicted on Securities Fraud Charges
-
Nature
Twitter changed science — what happens now it’s in turmoil?
-
San Francisco Business Times
Peanut allergy drug developer Aimmune to cut 75 jobs as parent Nestlé looks to sell lead drug
-
The New Yorker
The C.E.O. of Anti-Woke, Inc.
Previous
